How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Cancer

Small Cell Lung Cancer Clinical Trials in the UK

Find clinical trials for small cell lung cancer (SCLC) in the United Kingdom. Explore treatment pathways including immunotherapy and novel agents.

Search Trials →Explore Pathway

Understanding Small Cell Lung Cancer

SCLC accounts for ~15% of lung cancers, affecting ~7,000 people per year in the UK. It grows and spreads faster than non-small cell lung cancer but initially responds well to chemotherapy and radiotherapy. It is strongly linked to smoking. About two-thirds of patients have extensive stage (spread beyond one lung) at diagnosis.

Treatment Pathway

Limited stage: concurrent chemoradiation (cisplatin + etoposide) with consolidative radiotherapy. Prophylactic cranial irradiation (PCI) may be offered to reduce brain metastases. Extensive stage: chemotherapy (cisplatin or carboplatin + etoposide) + immunotherapy (atezolizumab or durvalumab). Second-line: lurbinectedin (recently approved), topotecan, or tarlatamab (bispecific antibody targeting DLL3 - showing impressive results).

Clinical Trial Opportunities

Active UK SCLC trials include: bispecific antibodies (tarlatamab, BI 764532 targeting DLL3), ADCs targeting DLL3, new immunotherapy combinations, PARP inhibitors, and cancer vaccines. The aggressive nature of SCLC means clinical trials are particularly important for improving outcomes.